Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Japan Finalizes Deal for Pfizer’s COVID-19 Pills, Eyes Approval by Mid-February
February 1, 2022
- Japan Won’t Give 3rd-Shot Approval for Shionogi’s Jab with Booster Trial Alone
February 1, 2022
- MHLW Panel Holds Off Decision on Bayer’s CKD Med Kerendia
January 31, 2022
- Veklury Use in Mild COVID-19 Could Be Considered: MHLW
January 31, 2022
- MSD Moves Up Supply of 50000 Courses of Lagevrio to Japan
January 31, 2022
- Cost-Effectiveness Analysis Temporarily Halted for Zolgensma to Collect Long-Term Data
January 31, 2022
- MHLW Panel OKs Mix-and-Match HPV Vaccines in “Catch-Up” Program
January 31, 2022
- MHLW Council Deems Public Knowledge-Based Filings Acceptable for 8 Fertility Treatment Indications
January 28, 2022
- MHLW Sets Volume Thresholds for Drug Orders to Resolve Generic Shortages
January 28, 2022
- Japan Panel Agrees to Vaccinate Children under Free COVID-19 Inoculation Program
January 27, 2022
- Up to 3 Refills Permitted per Prescription, No Refilling for Drugs with Dosage Restrictions: Chuikyo
January 27, 2022
- Drug Pricing Rules to Be Applied to BMS’ CAR-T Therapy Abecma: Chuikyo
January 27, 2022
- PMDA to Place Top Priority on Safety Measures under Proposed Emergency Approval System: Chief Executive
January 25, 2022
- Lagevrio Should Not Be Given to Asymptomatic COVID Patients: MHLW
January 25, 2022
- Japan to Import Pfizer’s Pediatric Vaccine Next Month, Inoculations to Begin in March: Minister
January 25, 2022
- MHLW Panel Backs Wholesaler Data Use to Monitor Vaccine Shortages in Public Programs
January 25, 2022
- Providing Info on Investigational Drugs on Company Websites Violates PMD Law: MHLW
January 25, 2022
- Lilly’s Retevmo Up for PAFSC Review for Thyroid Cancer on Feb. 4; Lenvima-Keytruda Combo on Agenda for RCC
January 24, 2022
- No Major Safety Concerns for COVID-19 Jabs: MHLW Panels
January 24, 2022
- Promote Both Pfizer/Moderna Vaccines for Boosters: Health Minister
January 24, 2022
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…